Format

Send to

Choose Destination
See comment in PubMed Commons below
Horm Res Paediatr. 2010;74(4):259-66. doi: 10.1159/000289570. Epub 2010 Apr 30.

Height at start, first-year growth response and cause of shortness at birth are major determinants of adult height outcomes of short children born small for gestational age and Silver-Russell syndrome treated with growth hormone: analysis of data from KIGS.

Author information

1
Paediatric Endocrinology Section, University Children's Hospital, Tübingen, Germany. Michael.Ranke@med.uni-tuebingen.de

Abstract

BACKGROUND/AIMS:

There is limited information about adult height (AH) outcomes and the factors influencing outcomes of growth hormone (GH) therapy in short children born small for gestational age (SGA).

METHODS:

AH (SDS) and Δheight (SDS) from GH start to AH were analyzed in 161 SGA children who had reached AH (55 with Silver-Russell syndrome, SRS).

RESULTS:

SGA patients treated to AH were started on GH (median) 0.25 mg/kg/week at an age of 7.8 years with a height of -3.8 SDS. AH after 7.7 years was -2.2 SDS and -1.1 SDS below mid-parental height (MPH). AH (SDS) was explained by: height (SDS) at GH start (+), Δheight (SDS) 1st year on GH (+), years on GH (+), maternal height (SDS) (+), length (SDS) at birth (+), and the diagnosis of SRS (-) (explained variability 70%; error 0.6 SD). Gain in height (SDS) was explained by: Δheight (SDS) 1st year on GH (+), years on GH (+), height - MPH (SDS) at GH start (-) (explained variability 60%; error 0.7 SD).

CONCLUSIONS:

Algorithms for AH outcomes provides useful information about the potential of long-term growth on GH in short children born SGA.

PMID:
20431273
DOI:
10.1159/000289570
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Support Center